Emesis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Emesis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major emesis markets are expected to exhibit a CAGR of 4.18% during 2024-2034.

The emesis market has been comprehensively analyzed in IMARC's new report titled "Emesis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Emesis, commonly known as vomiting, is a physiological process characterized by the forceful expulsion of abdominal contents through the mouth and sometimes the nose. It is a complex reflex involving the coordination of muscles in the stomach, diaphragm, and abdominal wall. Emesis helps to expel harmful substances or irritants from the body and can be accompanied by a variety of symptoms. The indications preceding or accompanying this condition range from a sensation of nausea, increased salivation, and an uncomfortable feeling in the upper abdomen to palpitations, lightheadedness, and a fast heartbeat. The ailment can be distressing, weakening, and it may also lead to dehydration if not managed properly. Diagnosing the underlying cause of emesis requires a thorough medical evaluation. Physicians take into consideration the patient's medical history, the duration and frequency of vomiting, associated symptoms, and any potential triggers. Various diagnostic tools, like blood tests, imaging studies, and endoscopic procedures might be conducted to identify the root cause.

The increasing prevalence of numerous associated risk factors, including gastroenteritis, food poisoning, motion sickness, peptic ulcers, excessive alcohol consumption, etc., is primarily driving the emesis market. In addition to this, the inflating utilization of efficacious treatments, such as antiemetic medications, serotonin receptor antagonists, dopamine antagonists, and neurokinin-1 receptor antagonists to effectively mitigate the condition and prevent further complications is creating a positive outlook for the market. Moreover, the widespread adoption of dietary modifications and lifestyle adjustments, as they aid in minimizing triggers, managing symptoms, and enhancing overall well-being, is also bolstering the market growth. Apart from this, the rising usage of behavioral therapies, which encompass cognitive-behavioral techniques and biofeedback mechanisms, to address underlying triggers and promote healthier responses in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of acupuncture and acupressure interventions, since they focus on specific pressure points that help in regulating the body's nausea response, is also augmenting the market growth. Furthermore, the escalating application of innovative medical devices, such as transcutaneous electrical nerve stimulation (TENS) procedures, which target certain neural pathways to alleviate vomiting in individuals suffering from the condition, is expected to drive the emesis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the emesis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for emesis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the emesis market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the emesis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the emesis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current emesis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the emesis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the emesis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the emesis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of emesis across the seven major markets?
What is the number of prevalent cases (2018-2034) of emesis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of emesis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with emesis across the seven major markets?
What is the size of the emesis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of emesis?
What will be the growth rate of patients across the seven major markets?

Emesis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for emesis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the emesis market?
What are the key regulatory events related to the emesis market?
What is the structure of clinical trial landscape by status related to the emesis market?
What is the structure of clinical trial landscape by phase related to the emesis market?
What is the structure of clinical trial landscape by route of administration related to the emesis market?